Fineron 10 mg ( Finerenone )

Indications:
Finerenone is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Dosage & Administration:
Prior to Initiation of Kerendia: Measure serum potassium levels and estimated glomerular filtration rate (eGFR) before initiation. Do not initiate treatment if serum potassium is >5.0 mEq/L.

Recommended Starting Dosage: The recommended starting dose of Kerendia is based on eGFR.
≥60 eGFR (mL/min/1.73 m2): Starting dose 20 mg once daily
≥25 to <60 eGFR (mL/min/1.73 m2): Starting dose 10 mg once daily
<25 eGFR (mL/min/1.73 m2): Not Recommended
For patients who are unable to swallow whole tablets, Kerendia may be crushed and mixed with water or soft foods such as applesauce immediately prior to use and administered orally

Contraindications:
Finerenone is contraindicated in patients: Who are receiving concomitant treatment with strong CYP3A4 inhibitors, With adrenal insufficiency.

Side Effects:
The following serious adverse reactions are discussed elsewhere in the labeling: Hyperkalemia.

Storage Conditions:
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.